Takara Bio Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis.Tokyo, Japan, Jan 11, 2007 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis. Takara Bio's RetroNectin method was used under license in the clinical trial. For the Retro Nectin treatment, VM106 utilizes a retro virus vector to inject gp91, the normal treatment gene, into the extracted haematopoietic Adj. 1. haematopoietic - pertaining to the formation of blood or blood cells; "hemopoietic stem cells in bone marrow" haematogenic, haemopoietic, hematogenic, hematopoietic, hemopoietic stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. of the patient. Afterwards af·ter·ward also af·ter·wards adv. At a later time; subsequently. afterwards or afterward Adverb later [Old English æfterweard] Adv. 1. a sample of this is injected back into the patient. Copyright [c] 2007 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion